Selective autophagic degradation of glycolytic activator PFKFB3 contributes to maintaining intestinal epithelial barrier in inflammatory bowel disease
International Journal of Molecular Medicine · 10.12.2025 · 57 (2) · 1-16
DOI: 10.3892/ijmm.2025.5714 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 10.12.2025. Verfasst von Yiyang Pan und 8 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery Laboratory, Department of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing 400037, P.R. China. Hauptthemen laut MEDLINE: Phosphofructokinase-2, Autophagy, Glycolysis, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic idiopathic intestinal inflammatory disease with increasing incidence worldwide. However, the treatment of IBD is still limited and has not reached the expected therapeutic effect and new therapeutic targets are still to be discovered. Impaired autophagy and abnormal glycolysis levels were observed both in the in vivo and in vitro intestinal inflammation models, suggesting a relationship between autophagy and glycolysis in IBD. Subsequently, it demonstrated that autophagy negatively regulated the glycolysis of IECs by degradation of the key glycolytic enzyme 6‑phosphofructo‑2‑kinase/fructose‑2,6‑bisphosphatase 3 (PFKFB3). Co‑immunoprecipitation was employed to demonstrate that PFKFB3 ubiquitinated by fizzy and cell division cycle 20 related 1 E3 ligase and was then recognized by P62 autophagy receptor for degradation. Notably, increased PFKFB3 expression was detected both in patients with CD and DSS‑induced colitis. Inhibiting PFKFB3 enzyme activity relieved DSS‑induced intestinal inflammation and intestinal epithelial barrier damage. The present study proposed a combined therapy targeting autophagy and glycolysis might become a new choice for clinical treatment of IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Surgery Laboratory, Department of General Surgery, Xinqiao Hospital, Army Medical University, Chongqing 400037, P.R. China.
- General Surgery Laboratory, Department of General Surgery, Chongqing General Hospital, Chongqing University, Chongqing 401147, P.R. China.
Zitieren
APA
Pan, Y., Yang, F., Wang, L., Yang, T., Du, G., Xu, C., Yang, H., Yu, M., & Xiao, W. (2025). Selective autophagic degradation of glycolytic activator PFKFB3 contributes to maintaining intestinal epithelial barrier in inflammatory bowel disease. International Journal of Molecular Medicine, 57(2), 1-16. https://doi.org/10.3892/ijmm.2025.5714
Vancouver
Pan Y, Yang F, Wang L, Yang T, Du G, Xu C, et al. Selective autophagic degradation of glycolytic activator PFKFB3 contributes to maintaining intestinal epithelial barrier in inflammatory bowel disease. International Journal of Molecular Medicine. 2025;57(2):1-16. doi:10.3892/ijmm.2025.5714
BibTeX
@article{Pan2025,
author = {Pan, Yiyang and Yang, Feng and Wang, Liucan and Yang, Tianshu and Du, Guangsheng and Xu, Cong and Yang, Hua and Yu, Min and Xiao, Weidong},
title = {Selective autophagic degradation of glycolytic activator PFKFB3 contributes to maintaining intestinal epithelial barrier in inflammatory bowel disease},
journal = {International Journal of Molecular Medicine},
year = {2025},
volume = {57},
number = {2},
pages = {1--16},
doi = {10.3892/ijmm.2025.5714}
}
EUVIMED